Elimination of malignant clonogenic T cells from human bone marrow using chemoimmunoseparation with 2'-deoxycoformycin, deoxyadenosine and an immunotoxin.

abstract：:Donor leukocyte infusion (DLI) has well-documented activity in CML but the role of DLI in other diseases is less well defined. To evaluate the strategy in acute lymphocytic leukemia (ALL) we evaluated 44 ALL patients from 27 centers who were treated with DLI. Patients with persistent or recurrent disease received DLI ...

journal_title：Bone marrow transplantation

authors： Collins RH Jr,Goldstein S,Giralt S,Levine J,Porter D,Drobyski W,Barrett J,Johnson M,Kirk A,Horowitz M,Parker P

更新日期：2000-09-01 00:00:00

abstract：:Progression of Philadelphia-negative myeloproliferative (MPN) or myelodysplastic/myeloproliferative neoplasms (MDS/MPN) to acute myeloid leukemia (AML) is an adverse event in the course of the disease. Although allogeneic hematopoietic SCT (allo-SCT) is considered as the only curative therapy, few data exist on the ou...

journal_title：Bone marrow transplantation

authors： Cahu X,Chevallier P,Clavert A,Suarez F,Michallet M,Vincent L,Vigouroux S,Blaise D,Mariette C,Bilger K,Robin M,Yakoub-Agha I,Peffault de Latour R,Mohty M

更新日期：2014-06-01 00:00:00

abstract：:Estimation of CD34 expression is widely used to detect and quantify progenitor cells in haemopoietic tissues used as stem cell sources for transplantation. Mouse monoclonal antibodies to CD34 recognise different epitopes of the mucin-like sialoglycoprotein. These epitopes can be grouped into three classes by their dif...

journal_title：Bone marrow transplantation

authors： Titley I,Healy LE,Scott M,Amos TA,Gordon MY

更新日期：1995-10-01 00:00:00

abstract：:With the purpose of contributing to a better knowledge of the phenotypic characteristics and functional activity of umbilical cord blood (UCB) lymphocytes, we have carried out extensive immunophenotyping of these cells, evaluated their immune response to polyclonal and allogeneic activation and then compared these res...

journal_title：Bone marrow transplantation

authors： Paiva A,Freitas A,Loureiro A,Couceiro A,Martinho A,Simões O,Santos P,Tomaz J,Pais ML,Brêda Coimbra H

更新日期：1998-07-01 00:00:00

abstract：:A retrospective evaluation of 200 consecutive recipients of autologous peripheral blood stem cell transplantation (PBSCT) was conducted to ascertain the incidence and outcome of infection with Clostridium difficile. The diagnosis was confirmed in 14 patients with diarrhea (15 episodes) at a median of 33 days after ste...

journal_title：Bone marrow transplantation

authors： Bilgrami S,Feingold JM,Dorsky D,Edwards RL,Bona RD,Khan AM,Rodriguez-Pinero F,Clive J,Tutschka PJ

更新日期：1999-05-01 00:00:00

abstract：:The p19 dimer of interleukin 23 (IL-23) has been reported to have a major role in the pathogenesis of many experimental and clinical autoimmune diseases and may also have a prominent role in transplantation. We reasoned that deficiency of p19 in the allogeneic donor transplant might reduce the inflammation caused by a...

journal_title：Bone marrow transplantation

authors： Thompson JS,Chu Y,Glass JF,Brown SA

更新日期：2010-04-01 00:00:00

abstract：:G-CSF accelerates neutrophil recovery after autologous peripheral blood progenitor cell transplantation (aPBPCT), although the optimal timing for its administration is currently unknown. In order to establish the role and the optimal timing of administration of G-CSF after immunoselected CD34+ aPBPCT, we analyzed the ...

journal_title：Bone marrow transplantation

authors： Piccirillo N,Sica S,Laurenti L,Chiusolo P,La Barbera EO,Sorà F,Leone G

更新日期：1999-06-01 00:00:00

abstract：:Approaches to determine whether one transplant-related therapy is better than another include: (1) using experimental data, such as those from randomized controlled trials (RCTs); (2) using observational data, such as those from observational databases (ODBs) and (3) using conclusions from the structured quantificatio...

journal_title：Bone marrow transplantation

authors： Gale RP,Eapen M,Logan B,Zhang MJ,Lazarus HM

更新日期：2009-03-01 00:00:00

abstract：:Corticosteroid-resistant GVHD is difficult to manage and is associated with high morbidity and mortality. Cyclophosphamide (Cy) is an established immunosuppressive and cytotoxic drug widely used as part of pretransplant conditioning regimens. In a retrospective study of 15 patients who had not responded to corticoster...

journal_title：Bone marrow transplantation

authors： Mayer J,Krejcí M,Doubek M,Pospísil Z,Brychtová Y,Tomíska M,Rácil Z

更新日期：2005-04-01 00:00:00

abstract：:There exists limited information about the usefulness of hemopoietic stem cell transplantation (HSCT) for the treatment of patients with refractory Langerhans cell histiocytosis (LCH). We report here four Japanese pediatric patients with multisystem LCH disease who underwent HSCT between 1994 and 1997. Two of the four...

journal_title：Bone marrow transplantation

authors： Kinugawa N,Imashuku S,Hirota Y,Yamada K,Yamamoto A,Akazai A,Oda M,Miura N,Kakuta H,Sato T,Endo M,Takano T

更新日期：1999-10-01 00:00:00

abstract：:Acute graft-versus-host disease (aGVHD) is a frequent and major complication after allogeneic stem cell transplantation. For many years psoralen and ultraviolet (UV)-A light have been used in the treatment of chronic cutaneous graft-versus-host disease, but few patients have received PUVA therapy for aGVHD. We assesse...

journal_title：Bone marrow transplantation

authors： Wiesmann A,Weller A,Lischka G,Klingebiel T,Kanz L,Einsele H

更新日期：1999-01-01 00:00:00

abstract：:This retrospective analysis compared two regimens of fludarabine combined with i.v. BU 6.4 mg/kg (FB2) or BU 12.8 mg/kg (FB4) for allografting of AML in first CR. A total of 437 patients (median age: 50 years) were administered FB2 (n = 225, 51%) or FB4 (n = 212, 49%). Median follow-up time was 28 months. Use of FB2 r...

journal_title：Bone marrow transplantation

authors： Kharfan-Dabaja MA,Labopin M,Bazarbachi A,Hamladji RM,Blaise D,Socié G,Lioure B,Bermudez A,Lopez-Corral L,Or R,Arcese W,Fegueux N,Nagler A,Mohty M

更新日期：2014-09-01 00:00:00

abstract：:The efficacy and safety of oral valganciclovir was compared to ganciclovir i.v. in pre-emptive treatment of cytomegalovirus (CMV) in T-cell-depleted allogeneic stem cell transplant (allo-SCT) recipients. A therapeutic guideline was developed to allow the safe application of valganciclovir in allo-SCT recipients requir...

journal_title：Bone marrow transplantation

authors： van der Heiden PL,Kalpoe JS,Barge RM,Willemze R,Kroes AC,Schippers EF

更新日期：2006-04-01 00:00:00

abstract：:Posttransplant cyclophosphamide (PTCy:100 mg/kg) has been increasingly used in allogeneic hematopoietic stem cell transplantation, however, few studies compared different doses of PTCy. We conducted two consecutive prospective multicenter phase II studies to evaluate the safety and efficacy of 80 mg/kg of PTCy in 137 ...

journal_title：Bone marrow transplantation

authors： Sugita J,Kamimura T,Ishikawa T,Ota S,Eto T,Kuroha T,Miyazaki Y,Kumagai H,Matsuo K,Akashi K,Taniguchi S,Harada M,Teshima T

更新日期：2020-09-24 00:00:00

abstract：:The evolution of bone marrow transplantation (BMT) from an experimental to a conventional form of therapy has been accompanied by an evolution in BMT-related research. While biomedically-related research continues to be most prominent, research investigating various psychosocial issues raised in the BMT setting has in...

journal_title：Bone marrow transplantation

authors： Andrykowski MA

更新日期：1994-04-01 00:00:00

abstract：:Haploidentical bone marrow transplantation (BMT) is associated with a high risk of severe graft-versus-host disease (GVHD). While pan-T cell depletion of the graft is the most effective means of preventing severe GVHD, it is associated with delayed recovery of T cell function leading to fatal infections. We used two r...

journal_title：Bone marrow transplantation

authors： Mavroudis DA,Jiang YZ,Hensel N,Lewalle P,Couriel D,Kreitman RJ,Pastan I,Barrett AJ

更新日期：1996-05-01 00:00:00

abstract：:A 55-year-old man with acute myeloid leukemia in second relapse presented 4 months after haploidentical CD34+-selected hematopoietic stem cell transplantation (HSCT) with symmetric, progressive neurological deficits of the lower extremities. Although there was no molecular evidence for drug resistance in the cerebral-...

journal_title：Bone marrow transplantation

authors： Zeiser R,Grüllich C,Bertz H,Pantazis G,Hufert FT,Bley TA,Finke J

更新日期：2004-01-01 00:00:00

abstract：:The aim of this phase II study was to determine the feasibility of using two (tandem) courses of high-dose alkylating agents with bone marrow or peripheral blood progenitor cell support in women with stage IV breast cancer. Women with stage IV breast cancer who had achieved a CR or PR during conventional chemotherapy ...

journal_title：Bone marrow transplantation

authors： Bitran JD,Samuels B,Klein L,Hanauer S,Johnson L,Martinec J,Harris E,Kempler J,White W

更新日期：1996-02-01 00:00:00

abstract：:A potential link between arsenic (ATO)-based therapy and delayed hematopoietic recovery after autologous hematopoietic SCT (HSCT) for acute promyelocytic leukemia (APL) has previously been reported. We retrospectively reviewed the clinical histories of 58 patients undergoing autologous HSCT for APL at 21 institutions ...

journal_title：Bone marrow transplantation

authors： Mannis GN,Logan AC,Leavitt AD,Yanada M,Hwang J,Olin RL,Damon LE,Andreadis C,Ai WZ,Gaensler KM,Greene CC,Gupta NK,Kaplan LD,Mahindra A,Miyazaki Y,Naoe T,Ohtake S,Sayre PH,Smith CC,Venstrom JM,Wolf JL,Caballero L

更新日期：2015-01-01 00:00:00

abstract：:Patients undergoing bone marrow transplantation (BMT) have decreased levels of salivary Ig over long periods of time. However, shortly after transplantation, a transient rise of Ig concentration in their saliva gland is detected. In order to trace the origin of this Ig, seven BM donors were immunized with tetanus toxo...

journal_title：Bone marrow transplantation

authors： Chaushu S,Chaushu G,Garfunkel A,Slavin S,Or R,Yefenof E

更新日期：1994-12-01 00:00:00

abstract：:Autologous SCT (auto-SCT) introduces a reduced tolerance to chemotherapy even in patients with adequate engraftment, suggesting long-term effects of the transplantation procedure on the BM capacity. To study the hematopoietic cell compartment after auto-SCT, CD34(+) BM cells (n = 16) from patients at 6-9 months after ...

journal_title：Bone marrow transplantation

authors： Woolthuis C,Agool A,Olthof S,Slart RH,Huls G,Smid WM,Schuringa JJ,Vellenga E

更新日期：2011-01-01 00:00:00

abstract：:We conducted a single-arm prospective study in 50 patients who received the combination of an haploidentical stem cell graft and an unrelated umbilical cord blood unit for the treatment of hematological malignancies. The median time for neutrophil engraftment was 13 days (11-20 days), and for platelets was 15 days (11...

journal_title：Bone marrow transplantation

authors： Chen J,Wang RX,Chen F,Sun AN,Qiu HY,Jin ZM,Tang XW,Han Y,Fu ZZ,He GS,Miao M,Ma X,Wu DP

更新日期：2014-02-01 00:00:00

abstract：:An unblinded, historical controlled study of 49 bone marrow transplant (BMT) patients was carried out in our institution to assess the effect of oral pentoxifylline (PTX) on BMT regimen related toxicity (RRT). Twenty-eight consecutively treated BMT patients (17 allogeneic, 11 autologous) were entered into the PTX trea...

journal_title：Bone marrow transplantation

authors： van der Jagt RH,Pari G,McDiarmid SA,Boisvert DM,Huebsch LB

更新日期：1994-02-01 00:00:00

abstract：:Hematopoietic stem cell transplantation (HSCT) is becoming an increasingly recognized indication for treatment of autoimmune diseases and severe immune-mediated disorders. However, multicenter registry data have demonstrated higher than anticipated early toxicity, approximately 10% for autoimmune diseases in general, ...

journal_title：Bone marrow transplantation

authors： Burt RK,Patel D,Thomas J,Yeager A,Traynor A,Heipe F,Arnold R,Marmont A,Collier D,Glatstein E,Snowden J

更新日期：2004-11-01 00:00:00

abstract：:Nine individuals between 15 and 43 years of age with non-Hodgkin's lymphoma underwent allogeneic marrow transplantation following busulfan 16 mg/kg and cyclophosphamide 120 mg/kg. These individuals were not considered optimal candidates for autologous transplantation chiefly because of marrow involvement or resistance...

journal_title：Bone marrow transplantation

authors： Copelan EA,Kapoor N,Gibbins B,Tutschka PJ

更新日期：1990-01-01 00:00:00

abstract：:The role of high-dose therapy and autologous stem cell transplantation (ASCT) in the treatment of patients with Ewing's sarcoma (EWS) remains uncertain. From November 1985 to September 1994, 13 patients aged 16-30 years (median 20.5) received high-dose melphalan (HDM) 140-200 mg/m2 +/- 500 cGy TBI followed by ASCT for...

journal_title：Bone marrow transplantation

authors： Stewart DA,Gyonyor E,Paterson AH,Arthur K,Temple W,Schachar NS,Klassen J,Brown C,Russell JA

更新日期：1996-08-01 00:00:00

abstract：:Treatment with allogeneic hematopoietic stem cell transplantation (HSCT) is associated with short and long-term toxicities that can result in alterations in sexual functioning. The aims of this prospective evaluation were to determine: (1) associations between HSCT and increased sexual dysfunction 1 year after treatme...

journal_title：Bone marrow transplantation

authors： Noerskov KH,Schjødt I,Syrjala KL,Jarden M

更新日期：2016-06-01 00:00:00

abstract：:Myeloablative chemotherapy with autologous hematopoietic progenitor cell rescue has been evaluated in the treatment of children and young adults with brain tumors for whom conventional therapy is either too toxic (for example, radiotherapy in infants) or ineffective (for example, recurrent malignant tumors). With this...

journal_title：Bone marrow transplantation

authors： Marachelian A,Butturini A,Finlay J

更新日期：2008-01-01 00:00:00

abstract：:Autosomal-recessive hyper-IgE syndrome (AR-HIES) is a combined immunodeficiency recently found to be associated with mutations of DOCK8. Clinically, this disorder is characterized beside recurrent bacterial complications, in particular by an unusual susceptibility to extensive cutaneous viral complications and by a hi...

journal_title：Bone marrow transplantation

authors： Gatz SA,Benninghoff U,Schütz C,Schulz A,Hönig M,Pannicke U,Holzmann KH,Schwarz K,Friedrich W

更新日期：2011-04-01 00:00:00

abstract：:Incubation of CML marrow in long-term culture (LTC) conditions may result in selection of normal (Ph-) LTC-initiating cells (LTC-IC) as early as 10 days, and in production of Ph- clonogenic cells and mature end cells within 5 weeks. This was the rationale for using marrow cells from 10-day-old LTC to autograft nine ch...

journal_title：Bone marrow transplantation

authors： Coutinho LH,Chang J,Brereton ML,Morgenstern GR,Scarffe JH,Harrison CJ,Yin JA,Darbyshire PJ,Burdach S,Dexter TM,Testa NG

更新日期：1997-05-01 00:00:00